K9 Gold Announces Private Placement of up to 4,000,000 Units for Proceeds of up to $400,000August 05, 2025 4:31 PM EDT | Source: K9 Gold Corp.West Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - K9 Gold Corp. (TSXV: KNC) (FSE: 5GP0) (OTCQB: WDFCF) ("K9" or the "Company") is pleased to announce that it is engaging in a private placement (the "Private Placement") of up to 4,000,000 units (the "Units") at a price of $0.10 per Unit. Each Unit is comprised of one common share and o ...

U.S.-listed CEA Industries Inc. has completed a $500M private placement led by YZi Labs to adopt BNB as its primary treasury reserve. The company may raise up to an additional $750M via warrants and will rebrand as BNB Network Company with ticker BNC on August 6. Former Galaxy Digital co-founder David Namdar will serve as CEO.https://t.co/gzChTTvw0g ...

Core Viewpoint - Greenland Resources Inc. is conducting a non-brokered private placement to raise up to C$10 million for its Malmbjerg Project in Greenland, focusing on molybdenum and magnesium development [1][7]. Group 1: Offering Details - The private placement will consist of up to 6,666,667 units priced at C$1.50 each, with each unit including one common share and one warrant [1]. - Each warrant allows the purchase of one common share at C$2.00 for 24 months post-closing [1]. - The offering is expected to close around August 5, 2025, pending necessary regulatory approvals [4]. Group 2: Use of Proceeds - Proceeds from the offering will fund detailed engineering studies, magnesium metallurgical studies, capital expenditures, offtake negotiations, and general corporate purposes [1][8]. Group 3: Project Overview - The Malmbjerg Project is a 100% owned molybdenum deposit with magnesium as a byproduct, located in central east Greenland [7]. - The project has a capex of US$820 million, a levered after-tax IRR of 33.8%, and a payback period of 2.4 years based on a US$18 per pound molybdenum price [8]. - Proven and Probable Reserves are estimated at 245 million tonnes with a grade of 0.176% MoS2, equating to 571 million pounds of contained molybdenum [8]. Group 4: Market Context - The project aims to supply approximately 25% of the EU's total yearly molybdenum consumption and meet 100% of the EU's defense needs [8]. - The magnesium market is currently dominated by China, which holds an 89% market share [7]. Group 5: Advisory Agreement - Greenland Resources has engaged ECM Capital Advisors Ltd. for financial advisory services related to the offering, with a fee of $700,000 and issuance of 466,666 non-transferable warrants [5].

Core Viewpoint - First Phosphate Corp. is initiating a non-brokered private placement to raise a minimum of $1 million to meet existing investor demand [1][2]. Group 1: Offering Details - The Offering will include Flow-Through Shares priced at $0.50 each and Hard Dollar Units also priced at $0.50, with each Hard Dollar Unit consisting of one Common Share and one half of a Common Share purchase warrant [7]. - Proceeds from the Flow-Through Offering will be allocated to Canadian exploration expenses related to the Company's projects in Québec, while net proceeds from the Hard Dollar Unit Offering will support exploration, development activities, working capital, and general corporate purposes [2]. - The Offering is expected to close around August 22, 2025, and all securities issued will be subject to a four-month and one-day statutory hold period [2]. Group 2: Finder's Fees and Compensation - Eligible finders will receive a fee of up to 8% of the gross proceeds raised from subscribers they introduce, along with Compensation Warrants equivalent to up to 8% of the number of Hard Dollar Units or Flow-Through Shares issued [3]. - Each Compensation Warrant allows the holder to acquire one Common Share at a price of $0.50 until December 31, 2025, with the possibility of an accelerated expiry if the trading price exceeds $0.80 for five consecutive days [3]. Group 3: Company Overview - First Phosphate Corp. is focused on producing high-purity phosphate for the lithium iron phosphate (LFP) battery industry, emphasizing sustainable extraction and purification methods [8]. - The Company's flagship project, the Bégin-Lamarche Property in Quebec, features rare igneous anorthosite rock that produces high-purity phosphate with minimal impurities [8].

Core Insights - Shattuck Labs, Inc. has entered into a securities purchase agreement for a private placement financing expected to yield total gross proceeds of approximately $103 million, which will fund the development of SL-325 through multiple Phase 2 clinical trials [1][5] Group 1: Financing Details - The private placement is led by OrbiMed and includes participation from both new and existing investors such as Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital [2] - The financing will involve the issuance of 15,225,158 shares of common stock and pre-funded warrants for an aggregate of 37,410,188 shares, along with warrants for an additional 52,635,346 shares [3] - The purchase price for each share of common stock is set at $0.8677, with accompanying warrants having an exercise price of $1.0846 [3] Group 2: Clinical Development Plans - SL-325 is a potentially first-in-class DR3 blocking antibody aimed at treating Crohn's disease, ulcerative colitis, and other autoimmune diseases, with Phase 1 clinical trial enrollment expected to begin in the current quarter [4][9] - The anticipated net proceeds from the private placement will be used for the clinical development of SL-325, including multiple Phase 2 trials in inflammatory bowel disease (IBD) and another autoimmune disease [5] - The total proceeds from the private placement, combined with current cash and equivalents, are expected to fund operations into 2029 [1][5] Group 3: Company Overview - Shattuck Labs, Inc. specializes in developing treatments for autoimmune and inflammatory diseases, with a focus on novel therapeutics targeting TNF superfamily receptors [10] - The company is headquartered in Austin, Texas, and Durham, North Carolina, and is recognized for its expertise in protein engineering and the development of TNF receptor agonist and antagonist therapeutics [10]

Financial Strategy - Verb Technology 将使用私募获得的 5.58 亿美元资金开始囤积和质押 Toncoin [1]

Core Points - iSpecimen Inc. closed a private placement for approximately $1.75 million in gross proceeds, intended for marketing and working capital [1][2][3] - The company issued 1,559,828 shares of common stock at a price of $1.122 per share [2] - WestPark Capital, Inc. acted as the exclusive placement agent for the offering [3] Financial Details - The net proceeds will be allocated as follows: $500,000 for marketing and advertising services, with the remainder for working capital and general corporate purposes [1] - The offering closed on August 4, 2025 [2] Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare specimen providers for medical research [6] - The company utilizes proprietary cloud-based technology to facilitate the search for biospecimens across a network of healthcare organizations [6]

Company Strategy - Verb Technology 将更名为 TON Strategy Co (TSC)，旨在推出首家公开上市的 Toncoin (TON) 国库策略公司 [1] - 公司通过私募融资 558 million 美元，用于支持新的 TON 策略 [1] Investment & Funding - Kingsway Capital 领投了此次融资 [1] - 超过 110 家机构和加密货币原生投资者参与了此次融资 [1]

Core Points - AB Science S.A. successfully completed a private placement raising a total gross amount of EUR 2.55 million from a limited number of investors [1][3][4] Use of Proceeds - The net proceeds from the private placement will be used to finance ongoing activities, particularly focusing on the clinical development of the AB8939 program [3] Private Placement Details - The private placement involved the issuance of 2,276,787 new ordinary shares, each with one share warrant attached, without preferential subscription rights [4][5] - The issue price of one ABSA is EUR 1.12, representing a 24.68% discount to the volume-weighted average price over the three trading days preceding the price setting [6][7] Share Capital Impact - Following the issuance, the company's total share capital will be EUR 704,695.95, consisting of 63,706,916 ordinary shares, which could increase to 65,983,703 shares if all warrants are exercised [11][12] Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on August 7, 2025, and will be assimilated to existing shares [15] About AB Science - AB Science specializes in the research, development, and commercialization of protein kinase inhibitors, targeting diseases with high unmet medical needs [24]

Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].